Literature DB >> 25341551

Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience.

Claudio Cerchione1, Lucio Catalano, Anna Emanuele Pareto, Marco Picardi, Fabrizio Pane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25341551     DOI： 10.1007/s00520-014-2490-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  7 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 2.  European perspective on multiple myeloma treatment strategies in 2014.

Authors:  Heinz Ludwig; Pieter Sonneveld; Faith Davies; Joan Bladé; Mario Boccadoro; Michele Cavo; Gareth Morgan; Javier de la Rubia; Michel Delforge; Meletios Dimopoulos; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Philippe Moreau; Hareth Nahi; Torben Plesner; Jesús San-Miguel; Roman Hajek; Pia Sondergeld; Antonio Palumbo
Journal:  Oncologist       Date:  2014-07-25

3.  A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

Authors:  M D Green; H Koelbl; J Baselga; A Galid; V Guillem; P Gascon; S Siena; R I Lalisang; H Samonigg; M R Clemens; V Zani; B C Liang; J Renwick; M J Piccart
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

4.  Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study.

Authors:  Ruth Pettengell; Matthias Schwenkglenks; Robert Leonard; André Bosly; Robert Paridaens; Manuel Constenla; Thomas D Szucs; Christian Jackisch
Journal:  Support Care Cancer       Date:  2008-03-20       Impact factor: 3.603

5.  Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.

Authors:  Lodovico Balducci; Hafez Al-Halawani; Veena Charu; Jennifer Tam; Seta Shahin; Lyndah Dreiling; William B Ershler
Journal:  Oncologist       Date:  2007-12

Review 6.  Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Authors:  Jeffrey Crawford; David C Dale; Gary H Lyman
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

Review 7.  Quality of life and supportive care in multiple myeloma.

Authors:  Melda Cömert; Ajda Ersoy Güneş; Fahri Sahin; Güray Saydam
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831
  7 in total
  9 in total

1.  Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.

Authors:  Claudio Cerchione; Amalia De Renzo; Davide Nappi; Maria Di Perna; Roberta Della Pepa; Novella Pugliese; Lucio Catalano; Fabrizio Pane; Marco Picardi
Journal:  Support Care Cancer       Date:  2019-01-23       Impact factor: 3.603

2.  Safety and comfort of domestic bortezomib injection in real-life experience.

Authors:  Claudio Cerchione; Davide Nappi; Anna Emanuele Pareto; Maria Di Perna; Irene Zacheo; Marco Picardi; Fabrizio Pane; Lucio Catalano
Journal:  Support Care Cancer       Date:  2018-03-24       Impact factor: 3.603

3.  Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone.

Authors:  Claudio Cerchione; Lucio Catalano; Ilaria Peluso; Davide Nappi; Maria Di Perna; Dalila Salvatore; Ilaria Migliaccio; Marco Picardi; Fabrizio Pane
Journal:  Support Care Cancer       Date:  2016-10-10       Impact factor: 3.603

4.  Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.

Authors:  Claudio Cerchione; Davide Nappi; Maria Di Perna; Irene Zacheo; Anna Emanuele Pareto; Marco Picardi; Lucio Catalano; Fabrizio Pane
Journal:  Case Rep Hematol       Date:  2016-10-27

5.  Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.

Authors:  Claudio Cerchione; Amalia De Renzo; Maria Di Perna; Roberta Della Pepa; Novella Pugliese; Lucio Catalano; Fabrizio Pane; Marco Picardi
Journal:  Support Care Cancer       Date:  2016-11-03       Impact factor: 3.603

Review 6.  Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?

Authors:  Xavier Leleu; Francesca Gay; Anne Flament; Kim Allcott; Michel Delforge
Journal:  Ann Hematol       Date:  2017-12-27       Impact factor: 3.673

7.  Pegfilgrastim in Supportive Care of Hodgkin Lymphoma.

Authors:  Claudio Cerchione; Davide Nappi; Alessandra Romano; Giovanni Martinelli
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

Review 8.  Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

Authors:  Claudio Cerchione; Davide Nappi; Giovanni Martinelli
Journal:  Support Care Cancer       Date:  2021-05-14       Impact factor: 3.603

9.  Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.

Authors:  Claudio Cerchione; Davide Nappi; Gerardo Musuraca; Alessandro Lucchesi; Ilaria Cimmino; Fabrizio Pane; Amalia De Renzo; Giovanni Martinelli
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.